Despite decades of investigation, the causes of rheumatoid arthritis (RA) have remained elusive.
D
espite decades of investigation, the causes of rheumatoid arthritis (RA) have remained elusive. In fact, research has indicated that there is unlikely to be a single root cause. Different paths of investigation have provided sometimes contradictory lines of evidence leading to multiple biologic triggers setting off the autoimmune response that causes RA.
Recently, animal studies have produced findings that argue for a broader causal theory that supports a targeted “cure.” Researchers who developed a mouse model for RA found that it took multiple regulatory T cells, rather than any specific one, to prevent the immune system from generating the tissue-specific inflammation that is the hallmark of RA. The cumulative effect of an array of diverse T cells introduced into the mouse was more effective in mediating the RA response than the single T cell that investigators expected to activate the receptor and trigger an inflammatory response. It was the diversity of the array that protected against RA. If the diversity is not present, the researchers reported, the immune system attacks the joints.
“Our results, surprisingly, show that suppressing the immune response against a single target will not shut down the inflammatory response that causes rheumatoid arthritis.”
The Wistar Institute announced the results of this research in the May 2012 issue ofThe Journal of Immunology. Andrew Caton, PhD, the senior author, said, “Our results, surprisingly, show that suppressing the immune response against a single target will not shut down the inflammatory response that causes rheumatoid arthritis. Instead, an array of inflammation-stimulating antigens may be involved in causing the disease.” An array of regulatory T cells is required to temper it.
The mouse model investigations also pointed to a possible reason that RA affects membranes that line the joints. Regulating T cells also influenced receptor T cells to produce interleukin-17 (IL-17), which travels through the body’s lymphatic system. The lymphatic system drains into the joints. Caton suggests that, “…the joint inflammation is a side effect of the natural tendency of these cells [IL-17] to accumulate in these areas of the body.”
Source:
The Wistar Institute. Regulatory immune cell diversity tempers autoimmunity in rheumatoid arthritis [press release]. Philadephia, PA:Science Daily; May 8, 2012. Available at: http:// www.sciencedaily.com/releases/2012/05/120508142626.htm. Accessed May 21, 2012.
Oh S, Aitken M, Simons DM, et al. Requirement for diverse TCR specificities determines regulatory T cell activity in a mouse model of autoimmune arthritis [published online ahead of print March 26, 2012].J Immunol. doi:10.4049/ jimmunol.1103598.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer
July 23rd 2024In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More